drugset / Trial / NCT00887601

BOLD Functional Magnetic Resonance Imaging (fMRI) and Cerebral Blood Flow Measurements as Biomarkers for Cognition Enhancing Drugs (3134-006)

NCT00887601

Phase 1 Completed 32 enrolled Merck Sharp & Dohme LLC
RandomizedCrossoverDouble-blindDiagnostic

Summary

This study will evaluate functional magnetic resonance imaging (fMRI) and methods for measuring drug induced changes in cerebral blood flow as biomarkers for attention-improving drugs.

Timeline

Start
2007-08
Primary completion
2008-05
Completion
2008-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Donepezil Small molecule 5 mg
Subject MK3134 Unknown 1 mg
Subject MK3134 Unknown 5 mg
Subject MK3134 Unknown 25 mg

Indications